pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

667 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT783Endpoints586BioPharma Dive224onclive165BioSpace59Fierce Biotech57raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Updated: Early sales of Lilly’s obesity pill appear to trail Novo’s
    About 20,000 people are taking Eli Lilly’s obesity pill Foundayo after its first 20 days on the market, according to the company’s CEO David Ricks. This points to a markedly slower launch of the…
    Endpoints · 2mo ago↗ source
  • The R&D 15: How pharma's top companies spent, won and lost on drug research
    Talking over pharma pipelines with a major drugmaker's development chief, he noted that if you looked at the biggest 50 drugs by revenue, the final one on the list brought in about $4 billion last ...
    Endpoints · 2mo ago↗ source
  • Novartis unveils North Carolina factory as final new build in $23B US expansion
    Novartis on Thursday revealed its plans to build another factory in the US, with the Swiss drugmaker noting that it has now allocated every dollar of its $23 billion promise to expand ...
← prev
page 25 of 27
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 2mo ago
↗ source
  • AbbVie faces questions about Skyrizi competition from J&J
    Threats to AbbVie's immunology dominance took center stage on the company's first-quarter earnings call Wednesday morning, as analysts pressed executives on their defense strategy. The heart of t…
    Endpoints · 2mo ago↗ source
  • FDA, AstraZeneca prep for oncology adcomm
    The FDA is set to convene its first advisory meeting of oncology experts in about nine months, with a couple of AstraZeneca drugs as the focus of the discussion. Details about the meeting of the ...
    Endpoints · 2mo ago↗ source
  • Bristol Myers reaches a crossroads as a make-or-break year takes shape
    Bristol Myers Squibb is facing a bit of an identity crisis. CEO Chris Boerner is nearly two and a half years into his tenure, with most of his time defined by
    Endpoints · 2mo ago↗ source
  • Pfizer earns positive Phase 3 in multiple myeloma; ICON overstated revenue
    Pfizer’s positive Phase 3 data in multiple myeloma: The company’s Elrexfio produced a “statistically significant and clinically meaningful improvement” in progression-free survival in patients with…
    Endpoints · 2mo ago↗ source
  • After Apellis deal, Biogen looks to fill early-stage pipeline
    Biogen is still looking at deals even after earmarking $5.6 billion to buy Apellis Pharmaceuticals earlier this month. “Most of what we're going to be focusing on is early-stage development and…
    Endpoints · 2mo ago↗ source
  • AstraZeneca rekindles UK relationship, pledges £300M to expand
    AstraZeneca and the UK government are back in each other's good graces. AstraZeneca on Wednesday said it is lifting its UK investment pause, with a £300 million budget to finish construction of a…
    Endpoints · 2mo ago↗ source
  • Chiesi signs $1.9B deal to acquire KalVista and its approved drug
    Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$K…
    Endpoints · 2mo ago↗ source
  • Should pharma be swinging bigger with AI? One top researcher wants to try
    RIO DE JANEIRO — Kyunghyun Cho says he's a free man once again. He makes that observation, semi-jokingly, while looking over countless rows of poster presentations on the sidelines of the Interna…
    Endpoints · 2mo ago↗ source
  • GSK CEO says team reorg could be in the cards pending upcoming Phase 3 readouts
    GSK is expecting several key late-stage readouts this year and, if they do not succeed, the company could change its team structure, CEO Luke Miels said during its first-quarter earnings call with…
    Endpoints · 2mo ago↗ source
  • MPM has collected three China drugs for its ‘best of both worlds’ strategy
    MPM BioImpact, a leading biotech investor, is going all in on its strategy to take China-born drugs to the global stage. Over the past year, its portfolio company K2 Therapeutics has amassed thre…
    Endpoints · 2mo ago↗ source
  • AstraZeneca cuts a couple of late-stage life-cycle trials after disappointing efficacy
    AstraZeneca said it had stopped several mid- and late-stage trials of some of its pipeline programs in the past few months, potentially limiting some of the life-cycle extensions it was hoping for.…
    Endpoints · 2mo ago↗ source
  • FDA debuts plan to collect real-time clinical trial data
    The FDA is launching a pilot program to collect and review clinical trial data in real time, giving scientific reviewers access to the data as it flows in, the agency announced Tuesday. AstraZene…
    Endpoints · 2mo ago↗ source
  • The crown for healthcare admin tech is still up for grabs
    A few years in, admin tech is still reigning as the king of health tech funding. Startups using AI to tackle mundane administrative work in healthcare, such as follow-ups,
    Endpoints · 2mo ago↗ source
  • Pfizer delays patent cliff for blockbuster Vyndamax
    Pfizer is staving off Vyndamax competition for another two years. The drug, also known as tafamidis, is among Pfizer’s top three best-selling medicines and vaccines. Vyndamax is approved for a he…
    Endpoints · 2mo ago↗ source
  • Hikma and Amarin's generic drug case heads to Supreme Court arguments
    When the Supreme Court hears arguments this week over a prescription-strength pill derived from fish oil, the entire generic drug industry will be watching. The case could have broad implications…
    Endpoints · 2mo ago↗ source
  • Rocket's PRV goes for $180M; Oruka targets $500M offering
    Rocket sells PRV for $180M: The New Jersey gene therapy maker sold the rare pediatric disease priority review voucher to an undisclosed buyer. Rocket Pharmaceuticals got the PRV after securing FDA ...
    Endpoints · 2mo ago↗ source
  • BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF
    The pharma company formerly known as BeiGene has plucked an experimental cancer drug from a Chinese biotech, aiming to go broader than its competitors. BeOne Medicines said it signed a license an…
    Endpoints · 2mo ago↗ source
  • Incyte claims double Phase 3 win in vitiligo, will file for approval
    Incyte intends to seek approval of its JAK1 inhibitor pill in the skin disease nonsegmental vitiligo after the drug, povorcitinib, hit in twin Phase 3 trials. The company revealed the successes ...
    Endpoints · 2mo ago↗ source
  • Updated: AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrel
    The pan-RAS space continues to gain momentum, as AbbVie signs up for a shot at entering a field with the potential to drastically alter the treatment of certain cancers. The Chicago-area pharma g…
    Endpoints · 3mo ago↗ source
  • FDA claims trial 'manipulation' tainted approval of ChemoCentryx drug
    The FDA accused ChemoCentryx of manipulating the results of a pivotal clinical trial used to approve the drug Tavneos, escalating the agency's effort to pull the treatment from the market. "New i…
    Endpoints · 3mo ago↗ source
  • Devoted Health’s 2025 revenue slips in turbulent Medicare Advantage market
    Devoted Health’s revenue and membership declined in 2025 for the first time since it launched health plans for seniors seven years ago. It’s a sign the high-profile startup, helmed by former Athe…
    Endpoints · 3mo ago↗ source
  • Adaptyv Bio reveals latest results in protein design competition
    RIO DE JANEIRO, Brazil — For the past two years, Adaptyv Bio has challenged the AI community to see how good today’s models are at designing proteins. Its latest competition, presented Monday at a…
    Endpoints · 3mo ago↗ source